Experimental drug RMC-5552 tested in recurrent glioblastoma – early trial ends
Disease control
Terminated
This early-phase trial tested the drug RMC-5552 in 7 adults with glioblastoma that had returned after standard treatment. The drug works by blocking a protein called mTOR, which may help stop cancer cells from growing. The study aimed to find the safest dose and check for side ef…
Phase: PHASE1 • Sponsor: Nicholas Butowski • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC